{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:46:50Z","timestamp":1783486010426,"version":"3.55.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Brazilian Journal of Infectious Diseases"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.bjid.2024.104497","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T04:22:44Z","timestamp":1733977364000},"page":"104497","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Activity of ceftolozane\/tazobactam and comparators against gram-negative bacilli: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART \u2013 Brazil), 2018\u20122021"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5464-2381","authenticated-orcid":false,"given":"Amanda Azevedo","family":"Bittencourt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8306-7646","authenticated-orcid":false,"given":"Vinicius Lima","family":"Faustino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6860-1740","authenticated-orcid":false,"given":"Paula de Mendon\u00e7a","family":"Batista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lays Paulino","family":"Leonel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina Della Negra","family":"de Paula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8897-1607","authenticated-orcid":false,"given":"Thales Jos\u00e9","family":"Polis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bjid.2024.104497_bib0001","unstructured":"Antimicrobial resistance: world Health Organization; 2021 [Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/antimicrobial-resistance."},{"key":"10.1016\/j.bjid.2024.104497_bib0002","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.bjid.2024.104497_bib0003","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s42770-023-00948-w","article-title":"Gram-negative bacilli carrying mcr gene in Brazil: a pathogen on the rise","volume":"54","author":"Costa-J\u00fanior","year":"2023","journal-title":"Braz J Microbiol"},{"key":"10.1016\/j.bjid.2024.104497_bib0004","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jhin.2021.11.011","article-title":"Trend analysis of carbapenem-resistant Gram-negative bacteria and antimicrobial consumption in the post-COVID-19 era: an extra challenge for healthcare institutions","volume":"120","author":"de Carvalho Hessel Dias","year":"2022","journal-title":"J Hospital Infect"},{"issue":"11","key":"10.1016\/j.bjid.2024.104497_bib0005","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1086\/507972","article-title":"Clinical culture surveillance of carbapenem-resistant pseudomonas aeruginosa and acinetobacter species in a teaching hospital in S\u00e3o Paulo, Brazil: a 7-year study","volume":"27","author":"Furtado","year":"2006","journal-title":"Infect Control Hospital Epidemiol"},{"issue":"11","key":"10.1016\/j.bjid.2024.104497_bib0006","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1007\/s10096-018-3352-1","article-title":"Immediate and later impacts of antimicrobial consumption on carbapenem-resistant Acinetobacter spp., Pseudomonas aeruginosa, and Klebsiella spp. in a teaching hospital in Brazil: a 10-year trend study","volume":"37","author":"Federico","year":"2018","journal-title":"Euro J Clin Microbiol Infect Dis"},{"issue":"4","key":"10.1016\/j.bjid.2024.104497_bib0007","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.bjid.2020.05.010","article-title":"Activity of ceftolozane-tazobactam and comparators against gram-negative bacilli: results from the study for monitoring antimicrobial resistance trends (SMART - Brazil; 2016-2017)","volume":"24","author":"Beir\u00e3o","year":"2020","journal-title":"Braz J Infect Dis"},{"issue":"Supplement_1","key":"10.1016\/j.bjid.2024.104497_bib0008","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1093\/cid\/ciad260","article-title":"A 7-Year Brazilian national perspective on plasmid-mediated carbapenem resistance in enterobacterales, pseudomonas aeruginosa, and acinetobacter baumannii complex and the impact of the coronavirus disease 2019 pandemic on their occurrence","volume":"77","author":"Kiffer","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.bjid.2024.104497_bib0009","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ajic.2021.09.018","article-title":"Impact of the COVID-19 pandemic on the incidence of multidrug-resistant bacterial infections in an acute care hospital in Brazil","volume":"50","author":"Polly","year":"2022","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.bjid.2024.104497_bib0010","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1590\/s1678-9946202264006","article-title":"Secondary infections in a cohort of patients with COVID-19 admitted to an intensive care unit: impact of gram-negative bacterial resistance","volume":"64","author":"Costa","year":"2022","journal-title":"Rev Inst Med Trop Sao Paulo"},{"key":"10.1016\/j.bjid.2024.104497_bib0011","doi-asserted-by":"crossref","DOI":"10.1590\/0037-8682-0090-2021","article-title":"Pre- and post-COVID-19 evaluation of antimicrobial susceptibility for healthcare-associated infections in the intensive care unit of a tertiary hospital","volume":"54","author":"Gaspar","year":"2021","journal-title":"Rev Soc Bras Med Trop"},{"issue":"2","key":"10.1016\/j.bjid.2024.104497_bib0012","doi-asserted-by":"crossref","first-page":"92","DOI":"10.53986\/ibjm.2022.0020","article-title":"Rising incidence of carbapenem resistant isolates: an Argentinian hospital\u2019s experience. More trouble in the aftermath of the COVID-19 pandemic","volume":"4","author":"Castro","year":"2022","journal-title":"Iberoam J Med"},{"key":"10.1016\/j.bjid.2024.104497_bib0013","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1093\/jac\/dkx181","article-title":"Sparing carbapenem usage","volume":"72","author":"Wilson","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bjid.2024.104497_bib0014","doi-asserted-by":"crossref","first-page":"993","DOI":"10.3390\/antibiotics10080993","article-title":"Pharmacokinetic\/pharmacodynamic adequacy of novel \u03b2-lactam\/\u03b2-lactamase inhibitors against gram-negative bacterial in critically Ill patients","volume":"10","author":"Han","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.bjid.2024.104497_bib0015","doi-asserted-by":"crossref","first-page":"ofaa651","DOI":"10.1093\/ofid\/ofaa651","article-title":"Meta-analysis of clinical outcomes using ceftazidime\/avibactam, ceftolozane\/tazobactam, and meropenem\/vaborbactam for the treatment of multidrug-resistant gram-negative infections","volume":"8","author":"Wilson","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.bjid.2024.104497_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2019.114925","article-title":"In vitro activity of ceftolozane\/tazobactam against phenotypically defined Extended-Spectrum \u03b2-Lactamase (ESBL)-positive isolates of Escherichia coli and Klebsiella pneumoniae isolated from hospitalized patients (SMART 2016)","volume":"96","author":"Karlowsky","year":"2020","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.bjid.2024.104497_bib0017","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/phar.1609","article-title":"Ceftolozane\/tazobactam: a novel cephalosporin\/\u03b2-lactamase inhibitor combination","volume":"35","author":"Cho","year":"2015","journal-title":"Pharmacotherapy"},{"issue":"Suppl 1","key":"10.1016\/j.bjid.2024.104497_bib0018","doi-asserted-by":"crossref","first-page":"35","DOI":"10.37201\/req\/s01.10.2021","article-title":"Ceftolozane-tazobactam: when, how and why using it?","volume":"34","author":"L\u00f3pez Montesinos","year":"2021","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.bjid.2024.104497_bib0019","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.bjid.2020.05.010","article-title":"Activity of ceftolozane-tazobactam and comparators against gram-negative bacilli: results from the study for monitoring antimicrobial resistance trends (SMART \u2013 Brazil; 2016\u20132017)","volume":"24","author":"Beir\u00e3o","year":"2020","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.bjid.2024.104497_bib0020","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/jcph.2165","article-title":"Ceftolozane\/Tazobactam Probability of Target Attainment in Patients with Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia","volume":"63","author":"Gao","year":"2023","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.bjid.2024.104497_bib0021","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13613-022-01084-8","article-title":"Outcomes in participants with ventilated nosocomial pneumonia and organ failure treated with ceftolozane\/tazobactam versus meropenem: a subset analysis of the phase 3, randomized, controlled ASPECT-NP trial","volume":"13","author":"Martin-Loeches","year":"2023","journal-title":"Ann Intensive Care"},{"issue":"Suppl 2","key":"10.1016\/j.bjid.2024.104497_bib0022","article-title":"624. Probability of target attainment of ceftolozane\/tazobactam among adult patients with hospital-acquired pneumonia\/ventilator-associated pneumonia secondary to pseudomonas aeruginosa in Latin America","volume":"9","author":"Okuma","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.bjid.2024.104497_bib0023","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jgar.2021.11.011","article-title":"In vitro activity of ceftolozane\/tazobactam against Gram-negative isolates collected from ICU patients with lower respiratory tract infections in seven Asian countries \u2012 SMART 2017\u20132019","volume":"29","author":"Lob","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.bjid.2024.104497_bib0024","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically \u2012 eleventh edition: M07","year":"2018"},{"key":"10.1016\/j.bjid.2024.104497_bib0025","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jgar.2021.01.010","article-title":"Molecular characterization of clinical isolates of Enterobacterales with elevated MIC values for aztreonam-avibactam from the INFORM global surveillance study, 2012-2017","volume":"24","author":"Estabrook","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.bjid.2024.104497_bib0026","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1093\/jac\/dkaa345","article-title":"ResFinder 4.0 for predictions of phenotypes from genotypes","volume":"75","author":"Bortolaia","year":"2020","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 1","key":"10.1016\/j.bjid.2024.104497_bib0027","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1093\/ofid\/ofy346","article-title":"The importance of antimicrobial resistance monitoring worldwide and the origins of SENTRY antimicrobial surveillance program","volume":"6","author":"Fuhrmeister","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"Supplement_1","key":"10.1016\/j.bjid.2024.104497_bib0028","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1093\/ofid\/ofy345","article-title":"Antimicrobial resistance surveillance and new drug development","volume":"6","author":"Sader","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.bjid.2024.104497_bib0029","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2020.575536","article-title":"The experience of implementing a national antimicrobial resistance surveillance system in Brazil","volume":"8","author":"Pillonetto","year":"2021","journal-title":"Front Public Health"},{"key":"10.1016\/j.bjid.2024.104497_bib0030","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01256-21","article-title":"WHO critical priority escherichia coli as one health challenge for a post-pandemic scenario: genomic surveillance and analysis of current Trends in Brazil","volume":"10","author":"Fuga","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.bjid.2024.104497_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105887","article-title":"In vitro activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa causing urinary, intra-abdominal and lower respiratory tract infections in intensive care units in Portugal: the STEP multicenter study","volume":"55","author":"Garc\u00eda-Fern\u00e1ndez","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.bjid.2024.104497_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2020.115302","article-title":"Susceptibility trends of ceftolozane\/tazobactam and comparators when tested against U.S. gram-negative bacterial surveillance isolates (2012\u20132018)","volume":"100","author":"Shortridge","year":"2021","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.bjid.2024.104497_bib0033","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1093\/jac\/dkaa278","article-title":"Susceptibility trends of ceftolozane\/tazobactam and comparators when tested against European Gram-negative bacterial surveillance isolates collected during 2012-18","volume":"75","author":"Sader","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bjid.2024.104497_bib0034","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1093\/jac\/dkac184","article-title":"Ceftolozane\/tazobactam for hospital-acquired\/ventilator-associated bacterial pneumonia due to ESBL-producing Enterobacterales: a subgroup analysis of the ASPECT-NP clinical trial","volume":"77","author":"Paterson","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bjid.2024.104497_bib0035","doi-asserted-by":"crossref","first-page":"ofaa139","DOI":"10.1093\/ofid\/ofaa139","article-title":"Ceftolozane\/Tazobactam for treatment of severe esbl-producing enterobacterales infections: a multicenter nationwide clinical experience (CEFTABUSE II Study)","volume":"7","author":"Bassetti","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.bjid.2024.104497_bib0036","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/jac\/dkw374","article-title":"Efficacy of ceftolozane\/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials","volume":"72","author":"Popejoy","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bjid.2024.104497_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2020.115101","article-title":"Activity of ceftolozane-tazobactam and comparators when tested against bacterial surveillance isolates collected from patients at risk of infections caused by resistant gram-negative pathogens","volume":"98","author":"Pfaller","year":"2020","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.bjid.2024.104497_bib0038","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jiph.2022.02.009","article-title":"In-vitro activity of ceftolozane\/tazobactam against recent clinical bacterial isolates from two Saudi Arabian hospitals","volume":"15","author":"Bahabri","year":"2022","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.bjid.2024.104497_bib0039","doi-asserted-by":"crossref","first-page":"518","DOI":"10.3390\/medicina59030518","article-title":"Satisfactory In Vitro Activity of Ceftolozane- Tazobactam against carbapenem-resistant pseudomonas aeruginosa but not against klebsiella pneumoniae isolates","volume":"59","author":"S\u0119kowska","year":"2023","journal-title":"Medicina (Kaunas)."},{"key":"10.1016\/j.bjid.2024.104497_bib0040","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.bjid.2017.06.008","article-title":"Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013\u20132015)","volume":"21","author":"Pfaller","year":"2017","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.bjid.2024.104497_bib0041","article-title":"Occurrence of blaKPC gene in clinical isolates of Pseudomonas aeruginosa from Brazil","volume":"47","author":"JLdC","year":"2022","journal-title":"ABCS Health Sci"},{"key":"10.1016\/j.bjid.2024.104497_bib0042","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1099\/jmm.0.001273","article-title":"High mortality by nosocomial infections caused by carbapenem-resistant P. aeruginosa in a referral hospital in Brazil: facing the perfect storm","volume":"69","author":"Urzedo","year":"2020","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.bjid.2024.104497_bib0043","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jgar.2018.01.014","article-title":"Early detection of a hypervirulent KPC-2-producing Pseudomonas aeruginosa ST235 in Brazil","volume":"12","author":"de Paula-Petroli","year":"2018","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.bjid.2024.104497_bib0044","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jgar.2018.08.021","article-title":"Draft genome sequence of KPC-2-producing Pseudomonas aeruginosa recovered from a bloodstream infection sample in Brazil","volume":"15","author":"de Oliveira Santos","year":"2018","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.bjid.2024.104497_bib0045","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.cmi.2022.12.006","article-title":"Antibiotic resistance associated with the COVID-19 pandemic: a systematic review and meta-analysis","volume":"29","author":"Langford","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.bjid.2024.104497_bib0046","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.ajic.2020.06.192","article-title":"Could the COVID-19 pandemic aggravate antimicrobial resistance?","volume":"48","author":"Rossato","year":"2020","journal-title":"Am J Infect Control"}],"container-title":["The Brazilian Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1413867024007797?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1413867024007797?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T12:36:27Z","timestamp":1737808587000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1413867024007797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1413867024007797"],"URL":"https:\/\/doi.org\/10.1016\/j.bjid.2024.104497","relation":{},"ISSN":["1413-8670"],"issn-type":[{"value":"1413-8670","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activity of ceftolozane\/tazobactam and comparators against gram-negative bacilli: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART \u2013 Brazil), 2018\u20122021","name":"articletitle","label":"Article Title"},{"value":"The Brazilian Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bjid.2024.104497","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and The Author(s). Published by Elsevier Ltd. Published by Elsevier Espa\u00f1a, S.L.U. on behalf of British Society of Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"104497"}}